13 March 2017 - Today’s post is written by Davide Ruffo, Government Affairs Senior Manager, Public Affairs & Reimbursement, Eli Lilly and Company Italy.

I was recently at an event in the European Parliament that was literally standing room only. HTA experts, policy-makers, patients’ advocates and policy enthusiasts alike gathered to discuss the future of Health Technology Assessment (HTA) in Europe and to share national experiences. This just goes to show that EU HTA cooperation is set to be a key issue in Brussels in the coming months as EU institutions decide on the future of HTA beyond 2020.

Read Eli Lilly blog